Journal of biopharmaceutical statisticsHumansBayes TheoremClinical TrialsPhase I as TopicComputer Simulation
A Bayesian design for dual-agent dose optimization with targeted therapies.
José L Jiménez, Mourad Tighiouart
Published: 202610.1080/10543406.2025.2557533
Abstract
In this article, we propose a phase I-II design in two stages for the combination of molecularly targeted therapies. The design is motivated by a published case study that combines MEK and PIK3CA inhibitors; a setting in which higher dose levels do n…
Preview only. Read the full abstract at the source